Defy Medical review: the fifteen-year-old clinic in a market of six-month-old brands

Defy is a hybrid: a physical clinic at 4809 N. Armenia Ave, Suite #220, Tampa, and a telemedicine practice that its about page says offers "comprehensive health services via telemedicine in most states throughout the US." The exact state list isn't published anywhere on the site — a gap worth flagging if you're in a smaller market and need to confirm before you start filling out intake forms.

The same page names Dr. Justin Saya as "our medical director and lead practicing physician." That sounds unremarkable until you read the rest of this catalogue, where naming the person responsible for the prescriptions is the exception rather than the rule.

The practice bills itself as "concierge," which in Defy's usage means fee-for-service rather than white-glove-and-a-butler. You pay per consultation, per lab draw, per prescription. There's no monthly membership that unlocks the doctor.

The care team is physician-led — that phrase gets thrown around loosely, so it's worth being specific. Defy uses MDs and DOs, supported by nurse practitioners and clinical staff, with lab work interpreted by the prescribing clinician rather than a triage algorithm. The initial consultation is typically an hour. That's long by telehealth standards, where fifteen minutes is closer to the norm and some intake flows never involve a real conversation at all.

There's no quiz that routes you into a pre-set protocol. The clinical model assumes you show up with symptoms and a lab panel, and the clinician builds a plan from there. That's slower and more expensive than what Hims or Henry Meds does. For patients whose case is complicated — secondary hypogonadism, thyroid overlap, prior treatment failures — it's also more useful.

The biggest structural difference between Defy and the newer platforms isn't the drugs. It's who reads your labs and how much time they spend doing it.

The published service pages cover testosterone replacement, hormone therapy for women, menopause, thyroid therapy, weight loss and semaglutide, erectile dysfunction and Trimix, female sexual dysfunction, hair loss, joint pain, IV therapy, ketamine therapy, anabolic-androgenic therapies, vitamins and supplements, and online lab testing. Peptide therapy is named as a core service in the company's own marketing, though — unlike everything above — it has no service page of its own.

That is a wide catalogue for one clinic. For a patient with three or four overlapping issues, having one clinician touch all of them is genuinely useful. For a patient who wants a single drug at the lowest price, it's the wrong store.

Peptide therapy is where Defy's back catalogue shows, and where the site has gone quietest. There is no peptide service page, no product list and no published price. The blog still carries sermorelin explainers going back years; the storefront around them is gone.

The reason isn't mysterious. The FDA placed BPC-157 on its Category 2 bulk drug substances list in late 2023, which barred 503A pharmacies from preparing it, and the compounded-peptide category has been unsettled ever since. BPC-157 came off Category 2 in April 2026, and in July 2026 the FDA's Pharmacy Compounding Advisory Committee voted 8–6 with one abstention to recommend it for the 503A bulks list — against the agency's own reviewers. A recommendation is not a rule. Nothing has been added to the list.

Every clinic in this category has had to trim what it will prescribe, and Defy has visibly trimmed. The practical consequence for a prospective patient is simple: if you are going to Defy for a specific peptide, ask before you book, because the website will not tell you whether they still have it.

Hormone therapy is the older and more stable side of the practice. Testosterone replacement, injectable and topical, has been the core offering since founding. Bioidentical hormone replacement for women is offered in compounded formulations.

Defy prescribes semaglutide and tirzepatide. The compounded side has been in flux for two years. The FDA first declared the tirzepatide shortage resolved on 2 October 2024, re-declared it on 19 December 2024 after the Outsourcing Facilities Association sued, and took semaglutide off the list in February 2025. Enforcement wind-downs followed on both: 18 February and 19 March 2025 for tirzepatide, 22 April and 22 May 2025 for semaglutide. That eliminated the shortage-based legal pathway most DTC weight-loss brands were built on, leaving only the narrow patient-specific exception under 503A.

Defy's GLP-1 pricing isn't published. Its tirzepatide page explains why insurance isn't accepted in terms that are hard to read without a raised eyebrow: "To offer reliable and affordable pricing, Defy Medical does not accept insurance or communicate with insurance companies directly. That way our patients have a clear understanding of cost without insurance-related surprises." The page carries no cost.

For someone whose weight issue sits alongside hormone problems, thyroid dysfunction or metabolic syndrome, having one clinical team address the whole picture has obvious appeal. For someone who wants semaglutide and only semaglutide, a purpose-built DTC brand will be faster and cheaper.

The sequence: book an initial consultation, get a lab panel set by the clinical team based on your intake rather than by a fixed formula, then an extended telehealth appointment of roughly an hour in which the clinician reviews labs, discusses history and proposes a plan. If a prescription follows, it ships from whichever pharmacy fills it and is billed separately.

Not one number in that sequence is published. Not the consultation fee, not the lab panel, not the medication. We checked the service pages, the get-started page and the sitemap; there is no pricing page on the site. Prospective patients have to call the new-patient line, 813-328-2335, and have someone quote them. For a clinic whose entire pitch is being more serious than the storefronts, being less transparent about money than the storefronts is a strange place to land.

The patient app handles ongoing management once you're in the system: prescriptions, reorders, dosing, scheduling.

Labs are integral, not optional. The initial panel is full by design, and follow-up labs are part of the ongoing model for anyone on hormone or GLP-1 therapy. That's more monitoring than most DTC platforms build in — several category leaders will refill a GLP-1 prescription indefinitely off a single intake questionnaire and no bloodwork at all.

The tradeoff is cost and hassle. Defy's lab page says "We partner with LabCorp to offer our lab services" and directs patients to print a requisition and walk into a LabCorp draw station. Convenient. Also unpriced: the panel cost is a variable you cannot calculate in advance from anything public.

Short answer: if you don't want blood drawn regularly, Defy is the wrong clinic. If you do want your clinician making decisions off current data, this is closer to how endocrinology practices operate than what most telehealth brands provide.

The Tampa clinic is a real building with real exam rooms, which distinguishes Defy from providers that exist only as an app and a fulfillment contract. For patients local to central Florida, in-person visits are an option — useful for IV and ketamine therapy, and any workup that benefits from a physical exam.

For everyone else it's telemedicine: video visits, LabCorp for draws, mail-order or local pharmacy for medications. The company says most states are covered, but with no published list, patients in less-populated jurisdictions should confirm licensure before assuming they can enroll.

The in-person option matters more than it sounds. It's one thing to be treated by a clinician you've never met and never will. It's another to know that if something goes sideways there's a physical clinic with the same medical director and the same records.

Defy fits a specific patient: someone with a complicated case — multiple overlapping hormone or metabolic issues, prior treatment failures elsewhere, a symptom picture that doesn't map to a single-drug protocol. Someone who wants a clinician reading labs and adjusting doses rather than an algorithm auto-refilling a starter kit. Someone willing to pay per service and to sit through a full hour of intake.

It doesn't fit the patient who wants the cheapest possible semaglutide from the fastest possible funnel. It doesn't fit the patient who won't do labs. And it doesn't fit anyone shopping on sticker price, because there is no sticker.

A search of the FDA warning-letter database for "Defy Medical" returns no matching letters. That is a completed check with a negative result rather than a clean record: it covers letters under that exact name, and a letter issued to an affiliated compounding pharmacy would not appear under Defy's.

The broader environment is where things get complicated, and the complications aren't Defy-specific. The Category 2 listing of BPC-157 in late 2023, its removal in April 2026, the advisory committee's non-binding July 2026 recommendation, and the collapse of the GLP-1 shortage pathway across 2025 all hit every clinic prescribing compounded peptides and GLP-1s. Defy has adjusted its menu in response, which is what a responsible clinic should do.

Worth naming plainly: compounded therapy sits on shifting legal ground, and no clinic can insulate patients from that. If the next FDA decision goes against a peptide you're on, availability changes. That risk isn't unique to Defy. It's the price of admission for the whole compounded market.

The Trustpilot profile is unusual: 4.8 out of 5 across 4,111 reviews, 95% of them five-star, profile claimed April 2022. That is the highest rating and the largest review base of any provider in this catalogue, and the company has "Replied to 93% of negative reviews".

The caveats belong in the same breath. It is a paid Trustpilot profile, and Trustpilot's invite-to-review model means the sample skews toward customers the company actively solicited. Volume doesn't fix that: 4,111 solicited reviews measure solicited customers precisely, not patients generally. A 93% reply rate on negative reviews is still a real signal, and a rare one — most of this catalogue is well under half.

Defy Medical is the counterweight in a market that has been trending toward faster, cheaper, shallower for four years. Physician-led, lab-driven, fee-for-service, with a named medical director and a physical clinic behind the video call — this is what serious hormone medicine looked like before DTC platforms rewrote the category.

For a complicated case, that is closer to how the problem should be treated than what most competitors offer. For a simple case on a tight budget, it's overkill.

Two structural criticisms are fair, and they are the same criticism twice. Defy publishes no prices — not the consultation, not the labs, not the medication — while telling patients on its own page that avoiding insurance gives them "a clear understanding of cost." And it doesn't publish the states it can serve. Both are fixable. A clinic this established has no good excuse for either.

What Defy does well is what the newer entrants don't do at all: it puts a named clinician between the patient and the prescription pad, keeps labs in the loop, and offers a physical clinic as backstop. That is fifteen years of the same model, and a menu that has visibly adjusted to regulatory reality rather than pretending the reality doesn't exist.

Not for everyone, and priced — as far as anyone can tell from outside — accordingly. But for the patient it's built for, one of the more defensible options in the category.

Editorial note: This page is for informational purposes and doesn't constitute medical advice. Hormone, peptide, and GLP-1 therapy decisions should be made with a licensed healthcare provider familiar with your medical history.